Methotrexate is technically a chemotherapy drug, yes. The FDA classifies it as an antimetabolite, a type of medication originally developed to treat cancer. But if your doctor prescribed it for rheumatoid arthritis, psoriasis, or another autoimmune condition, the dose you’re taking is a fraction of what cancer patients receive, and the way it works in your body at that dose is meaningfully different.
How Methotrexate Works
Methotrexate blocks an enzyme your cells need to process folic acid, which is essential for making new DNA. Without that step, cells can’t replicate properly. In cancer treatment, this is the point: flood the body with enough methotrexate to stop fast-dividing tumor cells from multiplying. At the much lower doses used for autoimmune diseases, the drug doesn’t primarily work by killing cells. Instead, it dials down the overactive immune response that drives joint inflammation and skin flare-ups.
This distinction matters because the label “chemotherapy” carries a lot of weight. People hear it and immediately think of hair loss, severe nausea, and long hospital stays. Those experiences are tied to the high doses used in oncology, not the weekly low-dose tablet most rheumatology and dermatology patients take.
The Dose Difference Is Enormous
For rheumatoid arthritis, the typical starting dose is 7.5 mg once a week. Psoriasis patients usually start at 10 to 25 mg per week, with a ceiling around 30 mg. These are small, carefully spaced doses designed to manage inflammation without overwhelming the body.
Cancer doses operate on a completely different scale. Patients with acute lymphoblastic leukemia may receive 20 mg per square meter of body surface area weekly, but high-dose protocols for osteosarcoma or central nervous system lymphoma start at 500 mg per square meter and can go far higher. That’s potentially hundreds of times the amount an arthritis patient takes. The drug is the same molecule, but the clinical experience at these two dose levels barely resembles each other.
Why Doctors Call It a DMARD, Not Chemo
When rheumatologists prescribe methotrexate, they classify it as a conventional synthetic DMARD, short for disease-modifying antirheumatic drug. The American College of Rheumatology uses this category, and it signals that the medication’s job is to slow or halt the disease process in your joints, not to kill cancer cells. Other drugs in the same DMARD category have nothing to do with oncology.
So you’ll often see methotrexate described two ways depending on context. An oncologist treating lymphoma calls it chemotherapy. A rheumatologist managing joint inflammation calls it a DMARD. Both are correct for their setting. If you’ve been prescribed a weekly low-dose tablet or injection for an autoimmune condition, DMARD is the more accurate label for what’s actually happening in your treatment.
Side Effects at Low Doses
The most common side effects at autoimmune-level doses are nausea, fatigue, and mouth ulcers. Some people notice mild stomach upset on the day they take their weekly dose. These are generally manageable and often improve over time or with adjustments to how you take the medication.
Your doctor will likely prescribe folic acid supplements alongside methotrexate. Because the drug works by blocking folic acid metabolism, replacing some of that folic acid helps reduce side effects like nausea, mouth sores, and stomach problems. You’ll typically take folic acid on the days you’re not taking methotrexate (it’s usually avoided on the same day as your dose). Studies show that folic acid supplementation significantly reduces the number of people who have to stop methotrexate because of side effects.
More serious but less common concerns include effects on liver function and blood cell counts, which is why your doctor will order regular blood tests. These check that your liver is handling the medication well and that your blood counts remain in a healthy range. At the low doses used for autoimmune conditions, severe complications like significant hair loss or serious immune suppression are uncommon.
It’s Still Handled as a Hazardous Medication
One thing that can feel unsettling: pharmacies and hospitals handle methotrexate with the same safety precautions used for cancer chemotherapy drugs, regardless of what it’s being prescribed for. OSHA classifies it as a hazardous drug, meaning healthcare workers preparing or administering it wear double gloves, protective gowns, and follow strict disposal protocols. Traces of methotrexate have been detected in patients’ sweat and vomit, which is one reason these precautions exist for staff who handle it repeatedly.
This doesn’t mean the pill sitting on your counter is dangerous to take as prescribed. The handling rules are designed to protect workers from chronic, repeated low-level exposure over years, not to reflect the risk to a patient taking a prescribed dose. Still, it’s reasonable to wash your hands after handling the tablets and to follow any disposal instructions your pharmacy provides.
What This Means for You
If you’ve been prescribed methotrexate for arthritis, psoriasis, or a similar condition, you’re taking a medication with roots in cancer treatment, but at a dose and schedule that serve a completely different purpose. The weekly 7.5 to 25 mg your doctor prescribed is not the same clinical experience as high-dose chemotherapy protocols that can exceed 500 mg per square meter of body surface area. Your side effect profile, your day-to-day life on the medication, and the goals of your treatment are all distinct from what a cancer patient goes through.
It’s also worth knowing that methotrexate has been used for autoimmune conditions for decades. It remains one of the most widely prescribed DMARDs in the world because, for many people, it effectively controls disease progression at a dose that’s well tolerated over the long term.